Featured

Status

Health Topics

Any Category
Diseases
Nervous System Diseases
Clear Filters

Search Clinical Trials

88 Results
Completed
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
The cause of liver damage in people with ASA is unknown. However, because ASA is the only urea cycle disorder that is characterized by both liver damage and elevated levels …
Completed
Cognitive Behavior Therapy for Treating Anxiety in People With Dementia
Dementia is an illness that causes memory problems; changes in behavior; and difficulty with thinking, making decisions, and carrying out daily activities. Many people with dementia also have anxiety, and …
Baylor Role: Lead Sponsor
Terminated
Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)
Approximately 10,000 spinal cord injuries (SCI) occur each year, most of which occur in males (80%). Many of these patients develop neurogenic bladder dysfunction (NGB) characterized by overactivity of the …
Baylor Role: Lead Sponsor
Completed
Selegiline to Zelapar Switch Study in Parkinson Disease Patients
This is an open label, multicenter, 6 week study of the conversion from oral selegiline to orally disintegrating selegiline in PD patients with or without motor fluctuations, and currently taking …
Baylor Role: Lead Sponsor
Completed
Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study
This is a study to compare orally dissolving levodopa (Parcopa) to the conventional immediate release oral levodopa. This is a single-dose, double-blind, placebo controlled crossover trial in participants with Parkinson …
Baylor Role: Lead Sponsor
Withdrawn
Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease
The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if …
Baylor Role: Lead Sponsor
Completed
Dietary Supplements for the Treatment of Angelman Syndrome
AS is a neurologic disorder that may cause developmental delay, mental retardation, severe speech impairment, seizures, small head size, and problems with movement and balance in young children. AS is …
Baylor Role: Collaborator
Completed
Pregabalin in the Treatment of Essential Tremor
Overview We propose a single site, double-blind, placebo-controlled, cross-over design. Drug will be administered in 75mg capsules with a target dose of 300 mg/day. Pregabalin will be titrated upward as …
Baylor Role: Lead Sponsor
Terminated
Treatment of Subarachnoid Hemorrhage With Human Albumin
The proposed study was set up to evaluate the tolerability and safety of 25% human albumin (HA) therapy in patients with subarachnoid hemorrhage (SAH). It is estimated that 37,500 people …
Baylor Role: Lead Sponsor
Completed
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Traumatic brain injury (TBI) causes a spectrum of cerebrovascular dysfunction, ranging from impaired pressure autoregulation to severe global ischemia (inadequate blood flow). Pressure autoregulation is the ability of an organ …